Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, Canada

Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.

Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.

Disclosures

Dr. Lin has consulted with the following companies on Continuing Medical Education programs:

Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.

No clinical trials. No patents.

Recent Contributions to PracticeUpdate:

  1. Primary Prevention of CV and HF Events With SGLT2i, GLP-1RA, and Their Combination in T2D
  2. Protection Against SARS-CoV-2 After Covid-19 Vaccination and Previous Infection
  3. SARS-CoV-2 Reinfection in Previously Infected Persons With and Without Subsequent Receipt of a Single Dose of the BNT162b2 Vaccine
  4. Efficacy of the BNT162b2 Vaccine After Recovery From COVID-19
  5. Optimal Timing for Starting DOACs After Ischemic Stroke With Atrial Fibrillation
  6. Mobile Stroke Unit vs Usual Care for Acute Ischemic Stroke Management
  7. Sleep and Blood Glucose Control Under Standardised Meal Conditions
  8. Immunogenicity and Reactogenicity of Vaccine Boosters After Ad26.COV2.S Priming
  9. Duration of Protection by Covid-19 Vaccines
  10. Effectiveness of COVID-19 Vaccines Over 9 Months in North Carolina

Most Read This Week

Recently Updated